MITSUBISHI-HITACHI
19.5.2020 14:02:16 CEST | Business Wire | Press release
Mitsubishi Hitachi Power Systems (MHPS) ranks first in market share by megawatts for gas turbine orders in 2020 according to data obtained from McCoy Power Reports. First quarter global orders of 2,638 MW brought MHPS’ market share to 28.5 percent globally. This increase in gas turbine market share was largely responsible for worldwide order booking increasing 19.7 percent during MHPS’ fiscal year ending March 31, 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200519005485/en/
“The extremely competitive global gas turbine market has moved in our direction with a clear preference for our JAC gas turbines, which are more reliable than competitor’s gas turbines while providing record-setting fuel efficiency and output,” said Ken Kawai, MHPS President and Chief Executive Officer. “Sales of MHPS’ gas turbines in both the advanced class and aero-derivative segments have gained momentum as utilities, independent power producers and municipalities around the world seek to lower their electricity cost through our unique combination of proven reliability and world class performance.”
MHPS’ J-Series gas turbines first entered commercial operation in 2011 and hold world-record reliability at 99.5%. In addition, they deliver combined cycle efficiency greater than 64%. The installed fleet of J-Series gas turbines recently achieved one million hours of commercial operation worldwide, which is nearly double that of competitors’ similar sized gas turbines.
Boosting MHPS’ first quarter 2020 market share was an order for the first two renewable-hydrogen-capable JAC gas turbines for the Intermountain Power Agency in Delta, Utah. Dan Eldredge of the Intermountain Power Agency said, "We chose MHPS' JAC power trains because they offered the best overall solution for our power generation equipment requirements, including the fuel flexibility that will enable us to meet our incremental goals toward 100% carbon-free power generation by 2045. With MHPS' tools and support, we expect to reliably provide cleaner power for decades to come."
Forty-five J-Series gas turbines are in commercial operation, and total ordered capacity exceeds 25 GW globally. One hundred and four units have been technically selected in Brazil, Canada, Japan, Mexico, Peru, South Korea, Taiwan, Thailand, and the United States.
“The marketplace has recognized our efforts through a wave of technical selections and orders placed,” said Junichiro Masada, Senior Vice President, Co-Chief Technology Officer, and Deputy Head of Turbomachinery Headquarters, MHPS. “And we continue to improve our technology. For example, we recently synced to the grid in Takasago, Japan, and reached full load with the latest 60 Hz enhancement of the JAC, demonstrating record-setting output and combined cycle efficiency. Competitors are years away from entering operation with a gas turbine of this size or efficiency. In addition, we recently demonstrated a significant performance enhancement of the FT4000 at our test facility in West Palm Beach, Florida.”
The FT4000 aero-derivative gas turbine, with multiple active projects in North America and internationally, has tripled its global footprint in the past two years and captured significant market share in its class since the purchase of PW Power Systems (PWPS) in 2013. The PWPS FT4000 first entered commercial operation in 2015 and delivers industry-leading simple cycle efficiency, start time and ramp rate.
“We are proud that our technology has launched us to global leadership in the competitive gas turbine market,” said Ken Kawai, President and Chief Executive Officer. “We value the contributions of our employees around the world who are focused on bringing advanced technologies and energy solutions to the marketplace for affordable and reliable power supplies. We remain committed to enabling a decarbonized economy and helping to resolve the challenges facing our global society.”
About Mitsubishi Hitachi Power Systems, Ltd.
Mitsubishi Hitachi Power Systems, Ltd. (MHPS), headquartered in Yokohama, Japan, is a joint venture formed in February 2014 by Mitsubishi Heavy Industries, Ltd. and Hitachi, Ltd. integrating their operations in thermal power generation systems and other related businesses. MHPS recently announced that its name will soon change to Mitsubishi Power. MHPS today ranks among the world’s leading suppliers of equipment and services to the power generation market, backed by 100 billion yen in capital and approximately 20,000 employees worldwide. The Company’s products include GTCC (gas turbine combined-cycle) and IGCC (integrated coal gasification combined-cycle) power plants, gas/coal/oil-fired (steam) power plants, boilers, generators, gas and steam turbines, geothermal power plants, AQCS (air quality control systems), power plant peripheral equipment and solid-oxide fuel cells (SOFC). For more information, please visit the Company's website at https://www.mhps.com .
Follow us at
https://twitter.com/MHPS_Global
, or http://www.linkedin.com/showcase/mhps
View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005485/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom